OPEN MINDS & Otsuka America Pharmaceutical Inc. Release Webinar On How Member Engagement Models Are Reshaping The Economics Of SMI Service Delivery

GETTYSBURG, PA. (August 3, 2025) — OPEN MINDS and Otsuka America Pharmaceutical Inc. have just released a webinar on Member Engagement Models Reshaping The Economics Of SMI Service Delivery.

Health care spending for adults with an SMI diagnosis is nearly three times higher than for those without. Much of this spending is driven by unmanaged co-occurring conditions and inconsistent treatment adherence—challenges that can be addressed through stronger consumer involvement in care planning and follow-through.¹

Listen to this fireside chat for expert insights on how emerging engagement models are reshaping both the clinical and financial dimensions of SMI service delivery. Real-world case examples are used to illustrate current challenges, utilization trends, and strategies demonstrating measurable improvements in adherence, access, and total cost of care.

Featuring:

Stuart Buttlaire, Ph.D., Vice President, Clinical Excellence and Leadership, OPEN MINDS*

Rick D. Gutierrez, Ph.D., Senior Associate, OPEN MINDS*

Arden Arslanyan, PharmD, Director, Managed Market Liaison, Otsuka America Pharmaceutical, Inc*

Learning Objectives:

• Explore the cost implications for health plans, and how improved consumer engagement may reduce total health care costs and improve clinical outcomes.
• Deepen understanding of the challenges and opportunities associated with engaging consumers with serious mental illness (SMI), and the impact on cost and quality in current program models.
• Examine innovative approaches and care models that enhance engagement, support clinical outcomes in SMI treatment, and improve care value.
• Gain insights from case studies highlighting effective strategies and lessons learned from the implementation of SMI-focused programs.

More About This Webinar:

For health plan executives and policymakers, improving outcomes for individuals with serious mental illness (SMI) requires more than clinical intervention—it requires meaningful consumer engagement. Without it, care plans may falter, resulting in preventable hospitalizations, higher emergency department utilization, and rising health care costs.

“Bettering the outcomes of health plans’ members with complex conditions are always a priority as a small percentage of consumers hold the most spend, said Stuart Buttlaire, Ph.D., Vice President, Clinical Excellence and Leadership, OPEN MINDS. “Health plans are looking for innovative, data-driven providers to partner with which we discuss here.”

Reference:

1. Heather Saunders, R. E. (2025, April 11). 5 key facts about Medicaid coverage for adults with mental illness. KFF. https://www.kff.org/mental-health/issue-brief/5-key-facts-about-medicaid-coverage-for-adults-with-mental-illness/

About OPEN MINDS

OPEN MINDS is a national market intelligence, management consulting, and marketing services firm specializing exclusively in the markets of the health and human service field that serve consumers with chronic conditions and complex support needs. OPEN MINDS mission is to provide payers, service provider organizations, and technology and scientific firms that serve these consumers with the market and management knowledge needed to improve their organizational efficiency and effectiveness.

For more information about OPEN MINDS’ management support expertise, go to https://openminds.com/about/

About Otsuka

Otsuka Pharmaceutical is a global healthcare company with the corporate philosophy: “Otsuka-people creating new products for better health worldwide.” Otsuka researches, develops, manufactures and markets innovative products, with a focus on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health. Learn more at https://www.otsuka-us.com.

For additional questions and inquiries, please contact Murray Beachtel, Senior Associate, OPEN MINDS at 717-334-1329 or openminds@openminds.com.

*Stuart Buttlaire and Rick D. Gutierrez are paid consultants of Otsuka America Pharmaceutical, Inc. (OAPI). Arden Arslanyan is an employee of OAPI.

© Otsuka America Pharmaceutical, Inc. All rights reserved. July 2025 00US25EUA0022